Trends of tuberculosis case detection, mortality and co-infection with HIV in Ghana: A retrospective cohort study

Eric Osei1,2*, Samuel Oppong3, Joyce Der3

1 Department of Population and Behavioural Sciences, School of Public Health, University of Health and Allied Sciences, Ho, Ghana, 2 Department of Public Health Graduate School, Yonsei University, Seoul, Republic of Korea, 3 Department of Epidemiology and Biostatistics, School of Public Health, University of Health and Allied Sciences, Ho, Ghana

* eosi@uhas.edu.gh

Abstract

Background

In an era of renewed commitment to accelerate the declines in Tuberculosis (TB) incidence and mortality, there is the need for National Tuberculosis Programmes (NTPs) to monitor trends in key indicators across a geographical location and to provide reliable data for direct measurement of TB incidence and mortality. In this context, we explored the trends of TB case detection, mortality and HIV co-infection, and examined the predictors of TB deaths in Ten districts of the Volta region of Ghana.

Methods

We conducted a retrospective cohort study of all TB cases registered from 2013 to 2017 in 10 districts of the Volta Region of Ghana. Case detection rate (CDR) was computed as the ratio of the number of new and relapse TB case notified to NTP to the number of estimated incident TB cases in a given year. Case fatality rates were estimated using data from 2012–2016 cohort of TB patients. Simple and multiple logistic regression were used to identify predictors of TB deaths with odds ratios and 95% confidence intervals estimated.

Results

Overall, there were 3,735 new and relapse TB patients who commenced anti-TB treatment during the period, representing the case detection rate of 40.1% with district variations. The CDR remained stable during the 5 years. Of the total cases, HIV status was documented for 3,144 (84.2%), among whom, 712 (22.6%) were HIV positive. The TB/HIV co-infection was more prevalent among children under 15 years of age (30.1%), males (30.6%), treatment after lost to follow-up patients (33.3%), and smear-negative pulmonary TB patients (29.1%). The prevalence of TB/HIV co-infection did not significantly change over the years. The overall case fatality rate was 13% (n = 486), with considerable variation among HIV-positives and HIV-negative TB patients (21.8% and 11% respectively) (p<0.001) and among districts.
TB/HIV co-infection, sputum smear-negative pulmonary TB and district of anti-TB treatment predicted TB mortality.

Conclusion

TB case detection rate was low and remained stable during the study period, whereas co-infection with HIV and mortality rates were quite high, indicating the need for feasible strategies such as active case finding to improve case detection, and improved case management to reduce mortality.

Background

Tuberculosis (TB) has burdened humanity for years and continue to pose a huge threat to public health and health systems [1]. Worldwide, about 10 million incident cases of TB occur in 2017. However, more than one-third of these cases were missed by the health systems and remain undetected [2]. Ensuring early diagnosis and prompt initiation of effective chemotherapy are key aspects of TB control programmes. Any delay in diagnosis and subsequent treatment of effective TB patients not only pose a high risk to communities but can also lead to more advanced disease state, which may result in more complications and death [3]. Recognising this, the Directly Observed Treatment Short-course (DOTS) strategy, introduced by the WHO, sets targets for all National TB Control Programmes to detect at least 70% of estimated infectious cases and successfully treat 85% of them in order to interrupt the transmission, reduce mortality and prevent emergence of drug resistance [4]. The End TB Strategy, which set target to reduce TB deaths by 95% and a 90% reduction in TB incidence by 2035, from the 2015 levels [5], also underscores the importance of early diagnosis, including universal drug susceptibility testing (DST) and systematic screening of contacts and high-risk groups to reduce the case-detection gap [6]. The strategy also set recommended targets level of ≥90% TB treatment coverage for all nations by 2025 at the least [7].

TB/HIV co-infection poses widespread diagnostic, management and economic challenges to many, particularly African countries, where the burden of HIV-associated TB is highest [7]. HIV infection has been known to increase the risk of developing active TB by accelerating disease progression or reactivating latent infection [8,9]. Additionally, TB/HIV co-infected patients, especially in the absence of antiretroviral therapy (ART), have a significantly worse prognosis. Knowing this, the WHO recommends systematic screening for TB symptoms among People Living with HIV (PLHIV) and vice versa, as an essential part of the care package, together with linkage to diagnostic and treatment services, where necessary [7]. In the WHO African region, about 87% of TB patients were tested for HIV in 2018, among whom, 29% were HIV-positive, representing 71% of the worlds TB/HIV co-infection burden [7].

Among all causes of deaths worldwide, TB ranked tenth, and it is the single most important cause of death from a single infectious agent since 2007. About 85% of TB deaths occurred in the WHO South-East Asia and African regions. In 2018, there were 15 HIV-negative TB mortalities and 3.3 HIV-positive TB mortalities per 100,000 population globally, and 37 and 20 per 100,000 population respectively in the WHO African Region [7]. The mortality rate of TB has been falling globally since 2000. Despite this feat, however, the world is not on track to achieve a 35% reduction in the total number of TB deaths by 2020, from the 2015 level, as set by the End TB Strategy. Reaching this milestone will require a faster rate of decline and case fatality rate not more than 10% by 2020 [7].
In Ghana, even though remarkable achievement has been made since adopting the DOTS strategy in the 1990s, TB remains a public health problem with a huge economic and health impact on individuals as well as the health system in general [10]. In 2017, there were an estimated 44,000 incident cases of TB in the country, however, only 14,550 (33%) cases were detected and notified to WHO, among whom, 21% were HIV-positive [2].

In an era of renewed ambition to accelerate the declines in TB incidence and mortality, there is the need for National Tuberculosis Programmes (NTPs) to monitor trends of key indicators across a geographical location, in order to provide reliable data for direct measurement of TB incidence and mortality [2]. This allows NTPs to report on the progress in reaching its goals and objectives. To the best of our literature search, no study in Ghana has examined the trends of TB case detection and mortality at the district level, as well as predictors of TB deaths. In this context, the present study explored the linear trends of TB case detection, mortality and co-infection with HIV, and examined the predictors of TB deaths across Ten districts of the Volta region of Ghana.

Materials and methods
Study settings and design
We conducted a retrospective cohort study of all TB cases registered from 2013 to 2017 in Ten TB Basic Management Units (BMU)/districts of the Volta Region of Ghana. A BMU is defined in terms of management, supervision, and monitoring responsibilities. Each unit had one or more treatment centres, laboratories, and a hospital. There is a coordinator who oversees TB control activities for the unit and maintains a master register of all TB patients being treated. The Volta Region is one of the 10 administrative regions of Ghana located at the Eastern part of the country. The region is bound to the north by the Northern Region, the south by the Gulf of Guinea, west by the Volta Lake and the east by the Republic of Togo. It is divided into three natural geographical belts namely the southern, middle and the northern belts and has 25 administrative districts, 377 health facilities, serving a population of over 2,789,211. There are 44 DOTS centres and 41 laboratories in the region that provide TB diagnosis and treatment services to TB clients. At the DOTS centres, TB diagnosis, treatment, and monitoring are done as per the National Tuberculosis Control Programme (NTBCP) guidelines. As in all other parts of Ghana, there are also TB/HIV collaborative activities at all DOTS centres in the region which aim to reduce the burden of TB among people living with HIV (PLHIV) and vice versa.

Sampling
For representativeness, stratified sampling approach was used to select participating districts. Strata were the geographical belts (southern, middle and northern) of the region. Five districts in the region did not have data from 2013, hence were excluded in the strata for selection. Ten (50%) districts were then selected from the remaining twenty. We randomly selected four districts each from the South (Keta, Ketu South, Central Tongu, and South Tongu), Northern (Nkwanta South, Krachi West, Kadjebi, and Krachi East); and two from the middle belt (Kpando and Hohoe) using probability proportion to the number of districts in each stratum. The data used to estimate CDR were that of patients with TB who were registered and commenced anti-TB treatment between 1\textsuperscript{st} January 2013 and 31\textsuperscript{st} December 2017 in the participating districts. Patients who were treated for TB between 2012 and 2016 constituted the population for estimation of mortality rate and its predictors.
Data source and extraction

Data were extracted from the master registers of each BMU in April 2018. The registers are provided by the Ghana NTBCP and are used by all districts in Ghana. They are used to record data of all patients with TB being treated at all DOTS centres in the districts, which is used to monitor the programme and report on indicators to the higher level. Data contained in the register include patients’ demographics; type and category of TB; initial and follow up sputum smear examination results; treatment outcomes; and HIV status and anti-retroviral treatment. Data were extracted directly into Microsoft Excel spreadsheet designed to capture all relevant variables. Data extractions were done by trained undergraduate students, supported by TB coordinators of participating districts. Variables such as age, sex, types of TB, co-morbidity with HIV/AIDS, and treatment outcomes were extracted for analysis. To ensure data quality and accuracy, the district TB focal persons were made to systematically check and compare each year’s data extracted with the source document. Discrepancies were checked and corrected accordingly. Data were cleaned to check for consistency and completeness of the data set before exporting for analysis.

Data handling and analysis

Extracted data were exported into Stata Version 13.1 (Stata Corp, College Station, Texas, USA) for analysis. Categorical variables were expressed in percentages and median and interquartile range (IQR) for continuous variables, they were compared using Pearson’s chi-square test or Fisher’s exact test and the independent-samples t-test accordingly to describe the study population. Chi-square for trend was used to examine linear trends. Simple and multiple logistic regression model with stepwise variable selection procedure were employed to identify independent predictors of TB deaths. Variables with p-value of <0.05 in the simple regression analysis were considered as candidate variables for inclusion in the multiple logistic regression analysis. The degree of association between dependent and independent variables was assessed using odds ratios (OR) with 95% confidence intervals (CI).

Outcome measures and definitions. Case Detection Rate (CDR) was computed as the number of TB cases notified during the period divided by the estimated annual TB incidence per 100,000 Ghanaian population [11] and was expressed in percentage. TB/HIV co-infection rate was measured as the percentage of TB patients tested for HIV who were HIV positive. Case fatality rate was assessed using data from 2012–2016 treatment cohorts of all TB patients. We used the WHO’s standard criteria [12] to define TB patients as shown in Table 1.

Ethical statement

Ethical approval was obtained from the University of Health and Allied Sciences Ethical Review Committee. Informed consent was not obtained since there was no direct contact with patients. Patients’ identifying information were not collected from the registers. Permission was sought from the Volta regional health director and district directors of participating districts before data were extracted. Data extractions were done in the presence of district health staff.

Results

General characteristics of study subjects

There were a total of 3,735 TB cases of all forms enrolled on treatment during the period in all 10 study districts, of whom ages ranged between 1 and 96 years, with median (interquartile range) age of 44 (19–69) years. Children below the age of 15 years constituted 4.3% (n = 161)
of all reported cases, while 15.4% (n = 574) were elderly (64+ years), among whom 63.6% were males and the rest females. Overall, males accounted for 62.5% (2,335) of all cases and the proportion of male cases increased with age; most of them (3,578; 95.8%) were new; 55 (1.5%) relapsed; 33 (0.8%) treatment after lost to follow-up; and 25 (0.7%) were treatment failure patients. Of all reported cases, 1,712 (45.8%) were pulmonary positive, 1,900 (50.9%) were pulmonary negative, while 116 (3.1%) were extrapulmonary TB patients. With regards to HIV status, 712 (19.1%) of them were co-infected with HIV, while the HIV status of 591 (15.8%) was unknown. The majority (1,125; 30.1%) were reported in the Ketu South district, followed by Keta (440; 11.8%), and the least (189; 5.1%) in Krachi East district (Table 2).

### Table 1. Case definitions of tuberculosis.

| Category | Definition |
|----------|------------|
| **Type of TB** | |
| Pulmonary smear-positive TB | Patient with at least two sputum specimens with sputum positive for acid-fast bacilli (AFB) by microscopy, or a patient with only one sputum specimen with smear-positive for AFB by microscopy and chest radiographic abnormalities consistent with active pulmonary TB. |
| Pulmonary smear-negative TB | Patient with symptoms suggestive of TB with at least two sputum specimens which were negative for AFB by microscopy, and with chest radiographic abnormalities consistent with active PTB or a patient with two sets of at least two sputum specimens taken at least two weeks apart, and which were negative for AFB by microscopy, and radiographic abnormalities consistent with pulmonary TB and lack of clinical response to one week of broad-spectrum antibiotic therapy. |
| Extra-pulmonary tuberculosis (EPTB) | TB of organs other than the lungs, such as lymph nodes, abdomen, genitourinary tract, skin, joints, bones, meninges, etc |
| **Patient category** | |
| New case | A patient who has never had treatment for TB before or has been on anti-TB treatment for less than four weeks |
| Relapse | A patient who has been declared cured or treatment completed of any form of TB in the past but who reports back to the health service and is found to be acid-fast bacilli smear-positive or culture-positive |
| Treatment failure | A patient who, while on treatment remained smear-positive or become again smear-positive at the end of the five months or later after commencing treatment. |
| Transferred in | A patient who started treatment in one health facility and transferred to the hospital to continue treatment and follow up |
| Treatment after loss to follow-up | Patients who have previously been treated for TB and were declared lost to follow-up at the end of their most recent course of treatment. (These were previously known as treatment after default patients.) |
| Others previously treated | Patients who have previously been treated for TB but whose outcome after their most recent course of treatment is unknown or undocumented |
| **Treatment outcome** | |
| Died | Patients who died from TB during treatment |

The overall case detection rate (CDR) of all forms of TB during the 5-years study period was 40.1%, (95%CI: 39.4–41.4), of which Kadjebi, Kpando and Ketu South districts were above and the rest below. Kpando (76.1%; 95%CI: 72.1–79.7) and Ketu South (77.4%; 95%CI: 75.2–79.5) had the highest CDR, while Krachi East (20.2; 95%CI: 17.8–22.9) and Krachi West (20.7%; 95%CI: 17.6–24.1) recorded the lowest CDR in the range of 20%, as shown in Fig 1. Case detection rate over the years remained fairly constant, with the highest rate of 42% recorded in the years 2013 and 2017, while 2016 had the lowest rate of 37% (Fig 2).
HIV testing and prevalence of TB/HIV co-infection

Of the 3,735 TB patients enrolled on treatment during the period, 3144 (84.2%) were tested for HIV, of whom 712 (22.6%; 95%CI: 21.2–24.2) had positive HIV results documented. The TB/HIV co-infection rate was highest among children under 15 years of age (34.1%; 95%CI: 26.2–42.6) and lowest (8.6%; 95%CI: 6.3–11.5) among the elderly (>64 years). Males had a higher...
prevalence rate (30.6%; 95%CI: 28.0–33.4) compared to females (17.9%; 95%CI: 16.3–19.7). Among the categories of TB patients, treatment after lost to follow-up patients had the highest co-infection rate (33.3%), followed by new cases (22.7%), and relapses (20.5%). The prevalence was 29.1% among smear-negative pulmonary TB patients compared to 6.6% for smear-positive pulmonary TB patients, while extra-pulmonary patients had 12% co-infection rate. Among the districts, the co-infection rate was highest in Ketu South (33%), Central Tongu (30.2%), and South Tongu (28%), all located in the southern part of Volta region; and lowest in Krachi East (9.2%) and Krachi West (11.9%) districts located in Northern Volta. With regards to the year of enrolment, the proportion of TB patients tested for HIV significantly increases from 72.5%
in 2013 to 94.1% in 2017 (p<0.0001), however, the co-infection rate remained fairly above 20% in all the years (Table 3).

**TB case fatality rates and trends**

Fig 3 shows the Overall trends in case fatality rates (CFR) stratified by HIV status. Of the 3,735 TB patients enrolled on treatment during the study period, 486 (13%; 95%CI: 12.0–14.1) of

| Characteristics | #TB cases | TB cases tested for HIV(n%) | HIV Positive TB n (%) | 95%CI |
|------------------|-----------|-----------------------------|-----------------------|------|
| **Age group(years)** |           |                             |                       |      |
| ≤14              | 161       | 138 (85.7)                  | 47 (34.1)             | 26.2–42.6 |
| 15–24            | 311       | 261 (83.9)                  | 28 (10.7)             | 7.2–15.1 |
| 25–34            | 601       | 509 (84.7)                  | 151 (29.7)            | 25.7–33.8 |
| 35–44            | 852       | 728 (85.4)                  | 214 (29.4)            | 26.1–32.8 |
| 45–54            | 743       | 617 (83.0)                  | 142 (23.0)            | 19.7–26.5 |
| 55–64            | 493       | 415 (84.2)                  | 89 (21.4)             | 17.6–25.7 |
| >64              | 574       | 476 (82.9)                  | 41 (8.6)              | 6.3–11.5 |
| **Sex**          |           |                             |                       |      |
| Male             | 1400      | 1172 (83.7)                 | 359 (30.6)            | 28.0–33.4 |
| Female           | 2335      | 1972 (84.5)                 | 353 (17.9)            | 16.3–19.7 |
| **Patient category** |       |                             |                       |      |
| New              | 3578      | 3011 (84.2)                 | 684 (22.7)            | 21.2–24.3 |
| Transferred in   | 19        | 14 (73.7)                   | 2 (14.3)              | 1.78–42.8 |
| Treatment after loss to follow-up | 33       | 30 (90.9)                   | 10 (33.3)             | 17.3–52.8 |
| Treatment failure | 25       | 24 (96.0)                   | 3 (12.5)              | 2.6–34.3 |
| Relapse          | 55        | 49 (89.1)                   | 10 (20.5)             | 10.2–34.3 |
| Other previously treated | 24 | 16 (66.7) | 3 (18.8) | 4.0–45.6 |
| **Type of TB**   |           |                             |                       |      |
| Pulmonary Positive | 1712     | 1510 (88.2)                 | 251 (16.6)            | 14.8–18.6 |
| Pulmonary negative | 1900     | 1528 (80.4)                 | 444 (29.1)            | 26.8–31.4 |
| Extra pulmonary  | 116       | 100 (86.2)                  | 12 (12.0)             | 6.3–20.0 |
| Not documented   | 7         | 6 (85.7)                    | 5 (83.3)              | 35.8–99.6 |
| **Districts of enrolment** |       |                             |                       |      |
| Central Tongu   | 197       | 149 (75.6)                  | 45 (30.2)             | 22.9–38.3 |
| Hohoe           | 412       | 400 (97.1)                  | 66 (16.5)             | 12.9–20.5 |
| Kadjebi         | 328       | 290 (88.4)                  | 51 (17.6)             | 13.4–22.5 |
| Keta            | 440       | 438 (99.5)                  | 66 (15.1)             | 11.8–18.8 |
| Ketu South      | 1125      | 884 (78.6)                  | 292 (33.0)            | 29.9–36.2 |
| Kpando          | 367       | 362 (98.6)                  | 86 (23.8)             | 19.5–28.5 |
| Krachi East     | 189       | 130 (68.8)                  | 12 (9.2)              | 4.8–15.6 |
| Krachi West     | 123       | 109 (88.6)                  | 13 (11.9)             | 6.5–19.5 |
| Nkwanta South   | 345       | 218 (63.2)                  | 35 (16.1)             | 11.4–21.6 |
| South Tongu     | 209       | 164 (78.5)                  | 46 (28.0)             | 21.3–35.6 |
| **Year of enrolment** |       |                             |                       |      |
| 2013            | 767       | 556 (72.5)                  | 114 (20.5)            | 17.2–24.1 |
| 2014            | 794       | 597 (75.2)                  | 140 (23.5)            | 20.1–27.1 |
| 2015            | 723       | 630 (87.1)                  | 139 (22.1)            | 18.9–25.5 |
| 2016            | 683       | 638 (93.4)                  | 136 (21.3)            | 18.2–24.7 |
| 2017            | 768       | 723 (94.1)                  | 153 (21.2)            | 18.2–24.3 |
| **Overall**     | 3735      | 3144 (84.2)                 | 712 (22.6)            | 21.2–24.2 |

https://doi.org/10.1371/journal.pone.0234878.t003
them were reported dead. There were 260 (10.7%; 95%CI:9.5–12.0) TB deaths among HIV-negative people during the 5 years, and an additional 148 (20.8%; 95%CI: 18.0–23.9) deaths among HIV-positive patients (p<0.001). The burden of TB deaths varied enormously among districts (range: 5–21.6%), with the highest reported in Central Tongu, South Tongu, Hohoe, and Keta (21.6%, 95%CI: 16.2–27.6; 20.7%, 95%CI: 15.7–26.6; 15.3%, 95%CI: 10.8–17.5 and 15%, 95%CI: 12.0–18.6) respectively, while Kadjebi (9.6%, 95%CI: 6.7–13.1), Krachi West (5%, 95%CI: 2.3–10.2) and Krachi East (3.1%, 95%CI: 1.1–6.0) had the lowest mortality rate. In 2016, the overall CFR was 14.8%, up from 9.5% in 2012 (an increase of 35.8%) and from 13.4% in 2015. Among HIV-negative patients, the rate rose faster, from 7.4% in 2012 to 13.3% in 2016 (an increase of 44.4%), while death rate among HIV-positive patients increased by 19.8% during the same period. There was however no evidence of a difference in the rise in annual TB mortality in all cases (Fig 3). Generally, Hohoe, Ketu South, and Krachi East had increasing trends in CFR rates, while the rest of the districts showed irregular trends (Fig 4).

### Predictors of TB deaths

Table 4 shows the crude and adjusted logistic regression results of predictors of TB mortality. Multiple regression analysis of all forms of TB showed that infection with HIV, smear-positive pulmonary TB, and district of TB treatment were independently associated with TB deaths. HIV-infected patients had 2.10 odds of dying during TB treatment compared to HIV-negative patients (95%CI: 1.67–2.65; P<0.001). Similarly, smear-positive pulmonary TB patients were 0.66 times (95% CI: 0.54–0.82; p<0.001) less likely to die during anti-TB treatment compared to smear-negative pulmonary TB patients. Compared to Ketu South, TB patients who were enrolled on treatment at Central Tongu, Hohoe, Keta and South Tongu were more likely to die during treatment, while those treated in Krachi East had 29% (95%CI: 0.13–0.76; P<0.01) decreased odds of dying. Factors such as age, sex and category of TB patients did not predict TB deaths.

![Fig 3. Trends of TB case fatality rate stratify by HIV status in 10 districts of Volta region, Ghana, 2012–2016. The mortality rates of HIV-positive TB are shown in red, rates of HIV-negative TB are shown in green and rates of all forms of TB are shown in black.](https://doi.org/10.1371/journal.pone.0234878.g003)
Fig 4. District trends in TB case fatality rate in 10 districts of the Volta region, Ghana, 2012–2016.

https://doi.org/10.1371/journal.pone.0234878.g004
## Discussion

### TB case detection rate and trends

Using retrospective surveillance data, we assessed 5-year trends of TB case detection, mortality and co-infection with HIV and compared the rates among 10 districts in the Volta region of Ghana. The study further assessed patients demographic and disease characteristics as independent predictors of TB deaths. Our analysis underscores significant district variation in the CDR and that underreporting of TB is a major problem in this part of the country, with an average of only 4 in 10 of the estimated cases being reported to the NTBCP. This translates to over 5,500 cases who remained undiagnosed or likely to have been given treatment by providers who are not connected to the NTBCP. Our finding falls short of the 90% target prescribed by the World Health Organization.  

### Table 4. Logistic regression of predictors of TB mortality during treatment.

| Variable                      | Died n (%) | COR  | 95%CI   | P-value | AOR  | 95%CI   | P-value |
|-------------------------------|------------|------|---------|---------|------|---------|---------|
| **Age group(years)**          |            |      |         |         |      |         |         |
| <15                           | 20(13.1)   | 1    |         |         |      |         |         |
| 15–24                         | 34(11.3)   | 0.85 | 0.47–1.53|         |      |         |         |
| 25–34                         | 78(13.6)   | 1.05 | 0.62–1.77|         |      |         |         |
| 35–44                         | 110(13.4)  | 1.03 | 0.62–1.71|         |      |         |         |
| 45–54                         | 102(14.3)  | 1.11 | 0.66–1.86|         |      |         |         |
| 55–64                         | 77(16.1)   | 1.27 | 0.75–2.16|         |      |         |         |
| >64                           | 65(11.6)   | 0.87 | 0.51–1.49|         |      |         |         |
| **Sex**                       |            |      |         |         |      |         |         |
| Male                          | 311(13.8)  | 1    |         |         | 0.467|         |         |
| Female                        | 175(12.9)  | 0.93 | 0.76–1.13|         |      |         |         |
| **Patient category**          |            |      |         |         |      |         |         |
| New                           | 466(13.5)  | 1    |         |         | 0.364|         |         |
| History of previous treatment | 20(16.4)   | 1.26 | 0.77–2.05|         |      |         |         |
| **HIV status**                |            |      |         |         |      |         |         |
| Negative                      | 260(10.7)  | 1    |         |         | 1    |         |         |
| Positive                      | 148(20.8)  | 2.25 | 1.80–2.82| <0.001  | 2.10 | 1.67–2.65| <0.001  |
| Unknown                       | 78(13.9)   | 1.30 | 0.99–1.71|         | 1.28 | 0.96–1.72| 0.095   |
| **Type of TB**                |            |      |         |         |      |         |         |
| Pulmonary negative            | 290(15.7)  | 1    |         | <0.001  | 1    |         |         |
| Extrapulmonary                | 9(8.4)     | 0.49 | 0.24–0.98|         | 0.62 | 0.31–1.26| 0.187   |
| Pulmonary positive            | 185(11.3)  | 0.68 | 0.56–0.82|         | 0.66 | 0.54–0.82| <0.001  |
| **Districts of treatment**    |            |      |         |         |      |         |         |
| Ketu South                    | 140(12.4)  | 1    |         | <0.001  | 1    |         |         |
| Central Tongu                 | 42 (21.6)  | 1.84 | 1.25–2.71|         | 2.16 | 1.45–3.20| <0.001  |
| Hohoe                         | 57 (15.3)  | 1.21 | 0.87–1.69|         | 1.64 | 1.14–2.33| 0.007   |
| Kadjebi                        | 31 (9.6)   | 0.71 | 0.47–1.07|         | 0.87 | 0.58–1.32| 0.529   |
| Keta                          | 66 (15.0)  | 1.18 | 0.86–1.63|         | 1.53 | 1.09–2.13| 0.012   |
| Kpando                        | 48 (13.2)  | 1.02 | 0.72–1.46|         | 1.19 | 0.83–1.71| 0.345   |
| Krachi East                   | 5(3.1)     | 0.21 | 0.08–0.53|         | 0.29 | 0.12–0.72| 0.008   |
| Krachi West                   | 6(5.0)     | 0.36 | 0.15–0.83|         | 0.48 | 0.21–1.14| 0.100   |
| Nkwanta South                 | 48 (14.3)  | 1.12 | 1.79–1.59|         | 1.35 | 0.94–1.95| 0.101   |
| South Tongu                   | 43 (20.7)  | 1.76 | 1.20–2.57|         | 2.12 | 1.44–3.15| <0.001  |

*adjusted for HIV status, type of TB and district of treatment

https://doi.org/10.1371/journal.pone.0234878.t004
by the WHO’s end TB strategy for all national control programmes in order to reduce the number of people falling ill with TB by 90% and TB deaths by 95% by 2035 [4]. Availability and proximity of diagnostic facilities and DOTS centres are likely to be an essential factor for case detection since districts with poor CDR such as Krachi East and Krachi West had the lowest diagnostic facility density, whereas Kpando and Ketu South with the highest laboratory and DOTS centre density [13] had the highest CDR above the 70%. This was also found by Obasanya and others [14] in their Nigerian study. The CDR appeared to have stagnated during the study period in all districts studied, a situation that has been partly attributed to the insufficient motivation of health personnel to detect and manage cases, dwindling of funds, inadequate private sector involvement, inadequate diagnostic centers and poor health-seeking behaviour of patients [15,16]. The most recent (2014) Ghana Demographic and Health Survey, for instance, reported that knowledge regarding TB was high among the populace. However, about 33% of women and 25% of men in the country would not disclose their TB disease status to their families, which may be driven by stigma [17]. The evidence for the best approach to increase TB case detection is incomplete [18], however, active case-finding has been identified as one such approach that has been successful [19]. A study in Vietnam, for instance, has highlighted the value of household contact tracing and investigation [20,21]. Other countries, such as India focuses on systematic screening in high-risk populations such as people living in urban slums [22]. Ohene and colleagues [23] however argue that, when considering a TB screening program, it is essential to simultaneously look at the overall health system functions and enhance capacity to facilitate early detection. Patient delay for seeking TB care may arise from various factors, including barriers in access to care such as costs of seeking care or stigma [24]. Addressing these barriers might have the secondary but important effect of encouraging symptomatic individuals to seek care.

**HIV test among TB patients and TB/HIV co-infection rate**

The deadly synergy between TB and HIV raises complexity and represent a considerable obstacle towards achieving global TB elimination target [25]. The offer of HIV test for TB patients presents an opportunity essential for providing the best care for TB/HIV coinfected patients, including antiretroviral therapy [2]. In this present study, an average of 84% of TB patients notified during the period had documented HIV test result. This is lower than the national average of more than 91% in 2017 [2] and what Osei and colleagues [26] previously reported in their study also in the Volta region of Ghana (92%). The percentage of TB patients with documented HIV results however, increased substantially from nearly 73% to more than 94% from 2013 to 2017 (a 23% rise), consistent with regional [13] and the global trends [2], an indication that the world is on track to achieve the 100% HIV testing coverage among TB patients by the 2025 target set in the End TB Strategy. The rate of documented HIV status among TB patients, however, varied considerably among districts studied, with the highest rate of over 95% achieved in Hohoe, Keta and Kpando districts and the lowest of below 70% found in Krachi East, and Nkwanta South districts. The reason for this variation could be attributed to the availability of trained personnel at DOTS centres in the districts to offer routine HIV counselling and testing.

Regional and countries prevalence studies have reported varied magnitude of TB/HIV co-infection rate, ranging between 2.9 and 72.3%, with an average rate of 23.5% [27]. Our pooled analysis from 10 districts in the Volta region of Ghana from 2013 to 2017 found a high co-infection rate among the cohort of TB patients. The 22.6% TB/HIV coinfection rate estimated in this study is higher than the national average of 19% estimated by the WHO in 2018 [7], what was reported in a previous study in the same region by Osei and colleagues (18.2%) [26].
and that reported in a recent national survey (14.7%) [28]. The rate is however lower than an estimate from the WHO’s African region (29%) and comparable to findings from other studies done in Ethiopia [29,30]. According to the sub-group analysis, the HIV infection rate among TB patients was highest among children under 15 years of age (30.1%) followed by people between 25 and 44 years. This finding is consistent with previous finding from the same study region [26] and that of other reports that have shown higher rate in persons aged 26–45 years who represent the sexually active age group [31,32]. Contrary to the previous report [26] however, males had the highest TB/HIV coinfection rate (30.6%) compared to 17.9% among females in this study. Furthermore, Ketu South, Central Tongu, South Tongu and Kpando, all urban districts had TB/HIV rate higher than the study average, while Krachi East and Krachi West (rural districts) recorded the lowest co-infection rate. The difference between the districts might be due to the difference in the demographic characteristics of the population and associated HIV/AIDS prevalence. The 2014 Ghana Demographic and Health Survey, for instance, reported that HIV/AIDS is more prevalent in urban areas than rural areas [17]. This sounds logical since HIV infection is known to be associated with an increased risk of developing active TB by accelerating disease progression [8,9]. Overall, the rate of TB/HIV co-infection has been falling globally since 2008 [2]. In this present study, however, the rate has stagnated around just over 20%, which is not different from what was previously reported from the same region [26]. This implies that activities to reduce HIV-associated TB need to be strengthened, which may include prevention, early detection and effective case management.

Trends and predictors of TB mortality

Tuberculosis case fatality rate (CFR) is an important indicator for monitoring progress towards the 2020 and 2025 milestones. In order to achieve the 2025 global milestone for reductions in TB deaths, a CFR of 6% or less is required by all NTPs [2]. The 13% overall CFR estimated in this present study compares favourably with what a previous South African study found (16.3%) in a 10-year electronic record review [33] and in Zimbabwe (22%) [34] but higher than findings reported in Ethiopia [35,36], Cape Town (3.7%) [37], Washington state, US (12.1%) [38] and Taiwan (12.3%) [39]. The differences in CFR in different settings might be due to the differences in the study sites, study period, the study design, and target population. Differences in the quality of case management cannot also be ruled out. Our results demonstrate that the burden of TB deaths vary considerably among districts, ranging from 5–21.6%, with the Southern (Central Tongu, South Tongu and Keta) and the Middle (Hohoe) belts recording the highest CFR, whereas districts in the Northern belt (Krachi East, Krachi West and Kadjebi) having the lowest mortality rates, suggesting relatively access to better case management in Northern Volta.

Globally, TB mortality rate fell by 42% between 2000 and 2018 (including 3.6% between 2017 and 2018) [7]. Conversely, our analysis shows considerable (35.8%) rise in the mortality rate between 2012 and 2016 (including 10% between 2015 and 2016). Additionally, unlike the global trend, the mortality rate for both HIV-negative and HIV-positive patients rose by 44.4% and 19.8% respectively. This suggests that the region is not on track to reach the End TB Strategy milestone of a 35% reduction in the total number of TB deaths between 2015 and 2020 since reaching the 2020 milestone requires a CFR of no more than 6% by 2020 [7].

Consistent with many other studies [26,40], we found that HIV-positive TB patients had increased odds of dying from the disease. This could potentially be attributed to drug interactions between the rifamycins (rifampin or rifabutin) and some antiretroviral agents [41], which may occur when obliviously given together, as well as malabsorption of anti-TB drugs among patients with advanced HIV [42], leading to low serum concentrations of drugs which
may lead to adverse treatment outcome [43]. Among HIV-infected individuals, cotrimoxazole prophylaxis therapy (CPT) has been known to reduce mortality by about 25–46% in Sub-Saharan Africa even in areas with high antimicrobial resistance. [44,45]. Studies from different populations [35,46,47] have also shown that TB/HIV co-infected patients who were not taking CPT were at highest risk of death. This study, however, did not have the data to confirm or refute this claim. Additionally, we found that patients who were pulmonary smear-positive were 0.66 times less likely to die during anti-TB treatment, compared to smear-negative pulmonary TB patients. Our finding corroborates with what Alobu et al. also found in their Nigerian study, where TB patient with negative sputum smear had 2.4 higher odds of dying during treatment compared to sputum smear positive patients [46]. This could be due to delays in the establishment of diagnosis among smear negative pulmonary TB patients [48]. Clinicians often are reluctant to treat TB patients whose diagnosis are not certain as a result of strict rules imposed on them by public health policies [49], which may result in further delays in initiation of anti-TB therapy that can lead to worse disease prognosis. Additionally, the presence of advanced HIV infection has been linked to atypical clinical presentation of TB, including smear-negative pulmonary TB and normal chest X-ray, making it difficult to diagnose TB [50]. In a systematic review and meta-analysis to identify the predictors on in-hospital deaths among pulmonary TB patients however, Carlos and colleagues did not find an association between positive sputum smear and in-hospital mortality [51].

Using Ketu South as a reference district, patients who had their anti-TB treatment from Central Tongu, Hohoe, Keta and South Tongu had increased odds of dying during treatment, whereas those who were treated at Krachi East were less likely to die. This variation may be due to differences in the quality of case management as well as differences in TB/HIV co-infection rate.

Our study is not without limitations. Firstly, due to the retrospective nature of the study, we could not independently corroborate the accuracy of data used in the analysis, nor could we collect additional data needed to confirm or refute our findings. Secondly, the presence of residual confounders is possible since data were either incomplete or not available to gather the necessary variables such as patient’s compliance, nutritional status, and the use of ART, CPT and other prophylaxis. Lastly, it is possible that some patients hid their history of previous anti-TB treatment at the time of diagnosis and were misclassified under a different category. Despite these limitations, the study did provide useful information on the trends of TB case detection rate, co-infection with HIV, and predictors of mortality in ten districts of the Volta region. Findings may be useful for TB programme planning and implementation.

Conclusion

Our analysis found low and stable TB case detection rate in the Volta Region of Ghana, with substantial district variations. Also, the prevalence of TB-HIV co-infection was quite high, more prevalent in urban districts, and remained steady over the years. The study further found high and increasing trends of TB case fatality rate, which was influenced by HIV infection, sputum smear-negative and treatment setting. Our results underscore three key needs for improving TB control in the region: 1) the need to adopt practical and feasible approaches for active case finding, which may involve training of local health personnel and volunteers, strengthening public-private partnerships and increasing laboratory density, in order to increase case detection. 2) embark on primary prevention programmes to reduce HIV infection among the general populace, and 3) improve case management, particularly among patients co-infected with HIV through early detection and initiation of ART, CPT or other prophylaxis in order to mitigate the burden of co-morbidity and to reduce death.
Supporting information

S1 File. Anonymized data set used for this study.
(XLSX)

Acknowledgments

Authors are grateful to health authorities and staff, particularly the TB coordinators of all participating districts for their support and permission to carry out and publish this study. We acknowledge the following persons who collected data; Daniel Adanfo, Bless Ativor Doepe, Andrews Owusu, and Augustine Goma Kupour, all past students of School of Public Health, University of Health and Allied Sciences, Ho, Ghana.

Author Contributions

Conceptualization: Eric Osei.
Formal analysis: Eric Osei, Samuel Oppong.
Investigation: Eric Osei, Samuel Oppong.
Methodology: Eric Osei.
Project administration: Eric Osei.
Supervision: Joyce Der.
Writing – original draft: Eric Osei, Joyce Der.
Writing – review & editing: Eric Osei, Samuel Oppong, Joyce Der.

References

1. Santos LC. Review: The Molecular Basis of Resistance in Mycobacterium tuberculosis and its management. Open J Med Microbiol. 2012; 02(01):24–36.
2. World Health Organization (WHO). Global tuberculosis report 2018. Geneva: WHO; 2018. Licence: CC BY-NC-SA 3.0 IGO
3. World Health Organization (WHO). Global Tuberculosis report 2013. Geneva: WHO
4. Keshavjee S, Farmer PE: Tuberculosis, Drug Resistance, and the History of Modern Medicine. N Engl J Med. 2012; 367:931–936. https://doi.org/10.1056/NEJMr1205429 PMID: 22931261
5. World Health Organization. Global tuberculosis Report 2017. Geneva: WHO.
6. World Health Organization (WHO). The end TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. A67/11–14
7. World Health Organization (WHO). Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO
8. Allen S, Batungwanayo J, Kerlikowske K, Lifson AR, Wolf W, Granich R, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis. 1992; 146(6):1439–44. 4. https://doi.org/10.1164/ajrccm/146.6.1439 PMID: 1456559
9. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989; 320(9):545–50. https://doi.org/10.1056/NEJM19880323200901 PMID: 2915665
10. Amo-Adjei J. and Awusabo-asare K. Reflections on tuberculosis diagnosis and treatment outcomes in Ghana. Archives of Public Health. 2013; 71(22), 1–8. https://doi.org/10.1186/2049-3258-71-2
11. World Health Organization (WHO). Tuberculosis case detection rates. https://www.who.int/whosis/whostat2006TuberculosisDOTSDetectionRate.pdf (access May 5, 2020)
12. World Health Organization (WHO). Definitions and reporting framework for tuberculosis, 2013 revision. ISBN 978 92 4 150534 5
13. Volta Regional Health Directorate. 2018 annual TB report, Ghana Health Services, Volta region (Unpublished)

14. Obasanya A, Abdurrahman ST, Oladimeji O, Lawson L, Dacombe R, Chukwueme N et al, Tuberculosis case detection in Nigeria, the unfinished agenda. Tropical Medicine and International Health. October 2015; volume 20 no 10 pp 1396–1402 https://doi.org/10.1111/tmi.12558 PMID: 26084031

15. Afoakwa E and Taylor J. Knowledge of tuberculosis and factors responsible for low case detection in the Amansie Central District, Ghana. South Sudan Medical Journal. February 2018; Vol 11 No 1.

16. Amenuvegbe GK, Anto F and Binka F. Low tuberculosis case detection: a community and health facility-based study of contributory factors in the Nkwanta South district of Ghana. BMC Res Notes. 2016; 9:330 https://doi.org/10.1186/s13104-016-2136-x PMID: 27357834

17. Ghana Statistical Service (GSS), Ghana Health Service (GHS), and ICF International. 2015. Ghana Demographic and Health Survey 2014. Rockville, Maryland, USA: GSS, GHS, and ICF International.

18. Kranzer K, Afnan-Holmes H, Tomlin K, et al. The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis. 2013; 17: 432–46 https://doi.org/10.5588/ijtld.12.0743 PMID: 23485377

19. Mhimbira FA, Cuevas LE, Dacombe R, Mkopi A, Sinclair D. Interventions to increase tuberculosis case detection at primary healthcare or community-level services. Cochrane Database of Systematic Reviews. 2017; Issue 11. Art. No.: CD011432

20. Fox GJ, Nhung NV, Sy DN, et al. Household-contact investigation for detection of tuberculosis in Vietnam. N Engl J Med. 2018; 378: 221–29. https://doi.org/10.1056/NEJMoa1700209 PMID: 29342390

21. Lung T, Marks GB, Viet Nhung N, et al. Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health. 2019; 7: e376–84. https://doi.org/10.1016/S2214-109X(18)30520-5 PMID: 30784638

22. Indian National Tuberculosis Control Programme. National strategic plan for tuberculosis elimination 2017–2025. 2017. https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf (accessed January 26, 2020).

23. Ohene Sally-Ann, Bonsu Frank, Nii Nortey Hanson-Nortey Ardon Toonstra, Sackey Adelaide, Lonnroth Knut. et al. Provider initiated tuberculosis case finding in outpatient departments of health care facilities in Ghana: yield by screening strategy and target group. BMC Infectious Diseases. 2017; 17:721 https://doi.org/10.1186/s12879-017-2843-5 PMID: 29191155

24. Osei E, Akweongo P and Binka F. Factors associated with DELAY in diagnosis among tuberculosis patients in Hohoe Municipality, Ghana. BMC Public Health. 2015; 15:721 https://doi.org/10.1186/s12889-015-1922-z PMID: 26220804

25. World Health Organization (WHO). WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization; 2013. WHO/HTM/TB/2012.1; WHO/HIV/2012.1

26. Osei E, Der J, Owusu R, Kofie P and Axame WK. The burden of HIV on Tuberculosis patients in the Volta Region of Ghana from 2012 to 2015: implication for Tuberculosis control. BMC Infectious Diseases. 2017; 17:504 https://doi.org/10.1186/s12898-015-1922-z PMID: 26220804

27. Gao J, Zheng P, Fu H. Prevalence of TB/HIV co-infection in Countries except China: A Systematic Review and Meta-Analysis. PLoS ONE. 2013, 8(5): e64915 https://doi.org/10.1371/journal.pone.0064915 PMID: 23741419

28. Addo KK, Ampofo WK, Owusu R, Bonsu C, Nartey N, Mensah GI, et al. First Nationwide Survey of the Prevalence of TB/HIV Co-Infection in Ghana. Journal of Tuberculosis Research. 2018; 6, 135–147.

29. Amare Desalegne, Tuberculosis and HIV Co-infection among Patients on Tuberculosis Treatment at Fenote Selam District Hospital, Amhara Regional State, Northwest Ethiopia. Global Journal of Medical Research: F Diseases. 2015; Volume 15 Issue 5 Version 1.0

30. Teweldemedhin Mebrahtu, Asres Negasi, Gebreyesus Hailay, and Asgedom Solomon Weldegebreal. Tuberculosis-Human Immunodeficiency Virus (HIV) co-infection in Ethiopia: a systematic review and meta-analysis. BMC Infectious Diseases. 2018; 18:676 https://doi.org/10.1186/s12879-018-3604-9 PMID: 30563476

31. Tarekegne D, Jemal M, Atanaw T, Ebabu A, Endris M, Moges F, et al. Prevalence of human immunodeficiency virus infection in a cohort of tuberculosis patients at Metema hospital, Northwest Ethiopia: a 3 years retrospective study. BMC Res Notes. 2016; 9:192 https://doi.org/10.1186/s13104-016-2004-8 PMID: 27026410

32. van der Werf MJ, Ködmön C, Zucs P, Hollo V, Amato-Gauci AJ, Pharris A. Tuberculosis and HIV coinfection in Europe: looking at one reality from two angles. AIDS. 2016; 30(18):2845–53. https://doi.org/10.1097/QAD.0000000000001252 PMID: 27755106
33. Christo JH, Kigozi NG, Chikobvu P, Botha S and Dingie van Rensburg HCJ. Risk factors for mortality in TB patients: a 10-year electronic record review in a South African province. BMC Public Health. 2017; 17:38 https://doi.org/10.1186/s12889-016-3972-2 PMID: 28061839

34. Takarinda KC, Sandy C, Masuka N, Hazangwe P, et al. Factors associated with mortality among patients on TB treatment in the Southern Region of Zimbabwe, 2013. Tuberc Res Treat. 2017; 6232071 https://doi.org/10.1155/2017/6232071 PMID: 28352474

35. Asgedom Solomon Weldegebreal, Tesfaye Daniel, Nirayo Yirga Legesse and Atey Tesfay Mehari. Time to death and risk factors among tuberculosis patients in Northern Ethiopia. BMC Res Notes. 2018 11:696 https://doi.org/10.1186/s13104-018-3806-7 PMID: 29555580

36. Getahun Belete, Ameni Gobena, Biadgilign Sibhatu and Medhin Girmay. Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia. BMC Infectious Diseases. 2017, 11:127 https://doi.org/10.1186/s12911-017-0697-1 PMID: 28061839

37. Horne David J, Hubbard Rebecca, Narita Masahiro, Exarchos Alexia, Park David R, Goss Christopher H et al. Factors associated with mortality in patients with tuberculosis. BMC Infectious Diseases. 2010; 10:258 https://doi.org/10.1186/1471-2334-10-258 PMID: 20799975

38. Lin Chou-Han, Lin Chou-Jui, Kuo Yao-Wen, Wang Jann-Yuan, Hsu Chia-Lin, Chen Jong-Ming, et al. Tuberculosis mortality: patient characteristics and causes. BMC Infectious Diseases. 2014; 14:5 https://doi.org/10.1186/1471-2334-14-5 PMID: 24387757

39. Russell G K; Merle C S; Cooke GS; Casas E C; da Fonseca M; du Cros P. Towards the WHO target of zero childhood tuberculosis deaths: an analysis of mortality in 13 locations in Africa and Asia. 2013; 17(12):1518–23 Int. J. Tuberc. Lung Dis

40. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, et al. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy. 2009; 29:503–10. https://doi.org/10.1592/phco.29.5.5.503 PMID: 19397460

41. Karo B, Krause G, Hollo V, van der Werf MJ, Castell S, Hamouda O, et al. Impact of HIV infection on tuberculosis mortality: patient characteristics and causes. BMC Infectious Diseases. 2014; 14:5 https://doi.org/10.1186/1471-2334-14-5 PMID: 24387757

42. Sileshi B, Deyessa N, Girma B, Melese M, and Suarez P. Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: a retrospective cohort study. BMC Infect Dis. 2013; (13):297.

43. Martinson NA, Karstaedt A, Venter WD, Omar T, King P, Mbengo T, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007, 21: 2043–2050. https://doi.org/10.1097/QAD.0b013e3282d48e7f PMID: 1785294

44. Basinga P., Moreira J., Bisoffi Z., Bisig B., & Van den Ende J. Why Are Clinicians Reluctant to Treat Smear-Negative Tuberculosis? An Inquiry about Treatment Thresholds in Rwanda. Medical Decision Making. 2007; 27(1), 53–60. https://doi.org/10.1177/0272989X06297104 PMID: 17237453

45. Hargreaves NJ, Kadzakumana O, Whitty CJ, Salaniponi FM, Harries AD, and Squire SB. ‘Smear-negative’ pulmonary tuberculosis in a DOTS program: poor outcomes in an area of high HIV seroprevalence. Int J Tuberc Lung Dis. 2001; 5: 847–854 PMID: 11573987

46. Almeida1 Carlos Podalirio Borges de, Ziegelmann2 Patrı́cias Klarmann, Couban Rachel, Wang4 Li, Busse 5 Jason Walter & Silva Denise Rossato Predictors of In-Hospital Mortality among Patients with Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Scientific report. 2018. 8:7230 | https://doi.org/10.1038/s41598-018-25409-5 PMID: 28740001